Treatment of septic shock with nitric oxide synthase inhibitor: The baby and the bathwater;Nitrogenoxidsyntasehæmmer-behandling ved septisk shock: Barnet og badevandet

Ugeskrift for Laeger

Volumn 166, Issue 11, 2004, Pages 1028-1029

  Møller, Kirsten ^a   Skinhøj, Peter ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE SYNTHASE; VASOCONSTRICTOR AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; NOTE; SEPTIC SHOCK; TREATMENT OUTCOME; VASODILATATION; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; HEMODYNAMICS; MORTALITY;

HEMODYNAMIC PROCESSES; HUMANS; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 1542572920     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Bochud P-Y, Calandra T. Science, medicine, and the future: pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003;326:262-6.
2. G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:13-20.
3. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004;32:1-12.
4. Lopez A, Lorente JA, Steingrub J et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
5. Rivers E, Nguyen B, Havstad S et al, and Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.